Goldman Sachs’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-30,000
| Closed | -$2.79M | – | 7140 |
|
|
2021
Q4 | $2.79M | Buy |
+30,000
| New | +$1.98M | ﹤0.01% | 3959 |
|
|
2021
Q1 | – | Sell |
-16,800
| Closed | -$1.29M | – | 6478 |
|
|
2020
Q4 | $1.29M | Buy |
+16,800
| New | +$1.26M | ﹤0.01% | 4033 |
|
|
2020
Q1 | – | Sell |
-75,000
| Closed | -$3.41M | – | 5668 |
|
|
2019
Q4 | $3.41M | Buy |
75,000
+30,000
| +67% | +$1.42M | ﹤0.01% | 3249 |
|
|
2019
Q3 | $2.06M | Hold |
45,000
| – | – | ﹤0.01% | 3506 |
|
|
2019
Q2 | $2.64M | Buy |
+45,000
| New | +$2.33M | ﹤0.01% | 3351 |
|
|
2018
Q4 | – | Sell |
-1,100
| Closed | -$51K | – | 5831 |
|
|
2018
Q3 | $51K | Sell |
1,100
-227,500
| -100% | -$9.22M | ﹤0.01% | 5289 |
|
|
2018
Q2 | $9.97M | Buy |
228,600
+223,300
| +4,213% | +$9.6M | ﹤0.01% | 2415 |
|
|
2018
Q1 | $209K | Sell |
5,300
-56,840
| -91% | -$2.21M | ﹤0.01% | 4982 |
|
|
2017
Q4 | $2.11M | Sell |
62,140
-13,260
| -18% | -$378K | ﹤0.01% | 3760 |
|
|
2017
Q3 | $1.92M | Buy |
75,400
+68,170
| +943% | +$1.56M | ﹤0.01% | 4033 |
|
|
2017
Q2 | $122K | Buy |
7,230
+5,060
| +233% | +$69.4K | ﹤0.01% | 6047 |
|
|
2017
Q1 | $32K | Buy |
2,170
+650
| +43% | +$9.63K | ﹤0.01% | 6404 |
|
|
2016
Q4 | $22K | Buy |
1,520
+930
| +158% | +$14.4K | ﹤0.01% | 6622 |
|
|
2016
Q3 | $10K | Sell |
590
-340
| -37% | -$5.64K | ﹤0.01% | 6876 |
|
|
2016
Q2 | $16K | Sell |
930
-30
| -3% | -$536 | ﹤0.01% | 6779 |
|
|
2016
Q1 | $19K | Sell |
960
-710
| -43% | -$11.4K | ﹤0.01% | 6763 |
|
|
2015
Q4 | $32K | Buy |
1,670
+800
| +92% | +$16.3K | ﹤0.01% | 6731 |
|
|
2015
Q3 | $17K | Sell |
870
-5,170
| -86% | -$176K | ﹤0.01% | 7071 |
|
|
2015
Q2 | $280K | Sell |
6,040
-1,640
| -21% | -$71.1K | ﹤0.01% | 5805 |
|
|
2015
Q1 | $336K | Sell |
7,680
-80
| -1% | -$3.72K | ﹤0.01% | 5537 |
|
|
2014
Q4 | $269K | Sell |
7,760
-13,630
| -64% | -$553K | ﹤0.01% | 5894 |
|
|
2014
Q3 | $896K | Buy |
21,390
+12,730
| +147% | +$568K | ﹤0.01% | 4720 |
|
|
2014
Q2 | $507K | Buy |
8,660
+930
| +12% | +$58.6K | ﹤0.01% | 5303 |
|
|
2014
Q1 | $487K | Sell |
7,730
-7,180
| -48% | -$476K | ﹤0.01% | 5304 |
|
|
2013
Q4 | $872K | Sell |
14,910
-6,720
| -31% | -$351K | ﹤0.01% | 4857 |
|
|
2013
Q3 | $1.14M | Sell |
21,630
-41,320
| -66% | -$2.77M | ﹤0.01% | 4479 |
|
|
2013
Q2 | $4.85M | Buy |
+62,950
| New | +$5.14M | ﹤0.01% | 2776 |
|
Goldman Sachs's ARNA Position: Q1 2022 in Review
Goldman Sachs sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 943,716 shares — an estimated $87.7M sold.
Goldman Sachs first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $101M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Goldman Sachs reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Goldman Sachs sold 943,716 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $87.7M.
- Goldman Sachs first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Goldman Sachs's Arena Pharmaceuticals Inc position peaked at $101M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.